论文部分内容阅读
目的:观察百令胶囊联合注射用灯盏花素对维持性腹膜透析患者微炎症的影响。方法:65例维持性腹膜透析6个月以上患者分为观察组33例和对照组32例。两组均予维持腹膜透析,并给予常规对症治疗。对照组在此基础上加用灯盏花素,观察组在对照组基础上再加用百令胶囊。治疗2周后,比较两组患者治疗前后血肌酐、尿素、血浆白蛋白、超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)等指标水平。结果:治疗后两组血肌酐、尿素均较治疗前明显降低(P<0.05),血浆白蛋白明显升高(P<0.05),且观察组血肌酐水平明显低于对照组(P<0.05),血浆白蛋白明显高于对照组(P<0.05)。两组hsCRP、IL-6水平较治疗前均有明显降低(P<0.01或0.05),且观察组hs-CRP、IL-6水平明显低于对照组(P<0.01)。结论:百令胶囊联合注射用灯盏花素对持续性腹膜透析患者微炎症状态控制良好,优于单用灯盏花素。
Objective: To observe the effect of Breviscapine combined with Breviscapine on microinflammation in maintenance peritoneal dialysis patients. Methods: Sixty-five cases of maintenance peritoneal dialysis for more than 6 months were divided into observation group (33 cases) and control group (32 cases). Both groups were to maintain peritoneal dialysis, and given conventional symptomatic treatment. In the control group, Breviscapine was added on the basis of this, and the observation group was given Bailing capsule on the basis of the control group. After 2 weeks of treatment, the levels of serum creatinine, urea, plasma albumin, hs-CRP and IL-6 were compared before and after treatment. Results: Serum creatinine and urea in both groups were significantly lower than those before treatment (P <0.05) and plasma albumin (P <0.05), and the serum creatinine level in the observation group was significantly lower than that in the control group (P <0.05) , Plasma albumin was significantly higher than the control group (P <0.05). The levels of hsCRP and IL-6 in both groups were significantly lower than those before treatment (P <0.01 or 0.05), and the levels of hs-CRP and IL-6 in the observation group were significantly lower than those in the control group (P <0.01). Conclusion: Breviscapine combined with Breviscapine for injection in patients with persistent peritoneal dialysis patients with controlled micro-inflammatory state is better than single breviscapine.